ResMed Inc. (NYSE:RMD) has earned an average rating of “Hold” from the thirteen brokerages that are covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $61.00.

RMD has been the topic of a number of research analyst reports. BidaskClub cut ResMed from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a report on Thursday, July 6th. Citigroup Inc. upgraded ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, August 2nd. BMO Capital Markets restated a “hold” rating on shares of ResMed in a report on Friday, May 12th. Finally, Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday, August 2nd.

In other news, insider Jr. Gregor K. Emmert bought 424,000 shares of the stock in a transaction dated Wednesday, June 28th. The shares were bought at an average cost of $0.06 per share, with a total value of $25,440.00. Also, Director Richard Sulpizio sold 65,887 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $77.82, for a total value of $5,127,326.34. Following the transaction, the director now directly owns 4,429 shares in the company, valued at $344,664.78. The disclosure for this sale can be found here. Insiders have sold 204,650 shares of company stock worth $15,516,845 over the last ninety days. 1.97% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the company. Gulf International Bank UK Ltd raised its position in shares of ResMed by 1.8% in the first quarter. Gulf International Bank UK Ltd now owns 42,044 shares of the medical equipment provider’s stock worth $3,025,000 after buying an additional 725 shares during the last quarter. National Pension Service raised its position in shares of ResMed by 37,521.7% in the first quarter. National Pension Service now owns 140,329 shares of the medical equipment provider’s stock worth $10,036,000 after buying an additional 139,956 shares during the last quarter. Bank of Montreal Can raised its position in shares of ResMed by 21.2% in the first quarter. Bank of Montreal Can now owns 175,344 shares of the medical equipment provider’s stock worth $12,619,000 after buying an additional 30,703 shares during the last quarter. Atria Investments LLC raised its position in shares of ResMed by 1.9% in the first quarter. Atria Investments LLC now owns 4,564 shares of the medical equipment provider’s stock worth $328,000 after buying an additional 83 shares during the last quarter. Finally, Fox Run Management L.L.C. raised its position in shares of ResMed by 19.7% in the first quarter. Fox Run Management L.L.C. now owns 7,900 shares of the medical equipment provider’s stock worth $569,000 after buying an additional 1,300 shares during the last quarter. 60.66% of the stock is currently owned by institutional investors.

ResMed (RMD) traded up 0.38% on Friday, reaching $73.07. 529,536 shares of the company traded hands. The firm has a 50 day moving average of $75.98 and a 200-day moving average of $72.38. ResMed has a one year low of $56.59 and a one year high of $79.63. The stock has a market capitalization of $10.39 billion, a PE ratio of 30.45 and a beta of 0.83.

ResMed (NYSE:RMD) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.02. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The business had revenue of $556.69 million for the quarter, compared to analysts’ expectations of $557.68 million. During the same period in the prior year, the business posted $0.74 earnings per share. The firm’s revenue was up 7.3% on a year-over-year basis. On average, analysts anticipate that ResMed will post $3.03 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Stockholders of record on Thursday, August 17th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.92%. This is a positive change from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date is Tuesday, August 15th. ResMed’s dividend payout ratio is presently 58.09%.

TRADEMARK VIOLATION WARNING: “ResMed Inc. (RMD) Receives Consensus Recommendation of “Hold” from Analysts” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/resmed-inc-rmd-receives-consensus-recommendation-of-hold-from-analysts/1505118.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Analyst Recommendations for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.